Clinical Trial Update: A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefapixant (MK-7264/AF-219) for chronic cough has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2020-11-02